Recursion Enters into Agreements to Acquire Cyclica and Valence
Tuesday, May 09, 2023
Recursion announced it has signed agreements to acquire Cyclica and Valence to bolster chemistry and generative AI capabilities.
The strategic acquisitions of Cyclica and Valence add industry-leading capabilities in digital chemistry, as well as machine-learning and artificial intelligence, combined with large-scale automated wet-laboratories and supercomputing capabilities, which enables to deploy the most complete, technology-enabled drug discovery solution in the biopharma industry.
The acquisition of Valence gives Recursion the opportunity to create a true centre of excellence for some of the most compelling AI/ML research in the world. With this newly integrated group housed in the Mila ecosystem, Recursion's team of researchers in AI and ML for drug discovery reaches a critical mass at a crucial time in the development of new AI algorithms for scientific discovery.
Cyclica and Recursion both believe in the value of industrializing drug discovery. Combining proteome-wide prediction of small molecule-target interactions into Recursion’s data universe will create one of the largest fit-for-purpose biological and chemical datasets in the drug discovery space.
